Kathryn Balmanno

3.9k citations

45 papers · 3.2k indexed · 1 hit paper · h-index 25

Oncology top 5%
- Cancer-related Molecular Pathways 6
- Colorectal Cancer Treatments and Studies 5
- Lung Cancer Research Studies 4
Molecular Biology top 5%
- Melanoma and MAPK Pathways 18
- Cell death mechanisms and regulation 11
- Protein Kinase Regulation and GTPase Signaling 10
- Ubiquitin and proteasome pathways 7
Cancer Research top 5%
Pathology and Forensic Medicine top 5%
Cell Biology top 5%
Epidemiology
- Neuroendocrine Tumor Research Advances 4

Co-authors: Simon J. Cook Kathryn Hadfield Claire R. Weston Rebecca Gilley Katherine Ewings Annette S. Little Matthew J. Sale Paul D. Smith
Cited by: Oncology Molecular Biology Cancer Research
Journals: Science (1 paper)Journal of Biological Chemistry (2 papers)Nature Communications (1 paper)
Partner nations: United Kingdom United States Australia

In The Last Decade

Kathryn Balmanno

45 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Kathryn Balmanno

Since Specialization

Citations

This map shows the geographic impact of Kathryn Balmanno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn Balmanno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn Balmanno more than expected).

Fields of papers citing papers by Kathryn Balmanno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn Balmanno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn Balmanno. The network helps show where Kathryn Balmanno may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kathryn Balmanno, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kathryn Balmanno Line = papers co-authored together Kathryn Balmanno links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1 Biochemical Journal ·Kathryn Balmanno,Andrew M. Kidger,Dominic P. Byrne,Matthew J. Sale,Nejma Nassman,Patrick A. Eyers,Simon J. Cook	2023	6
2	Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2 Molecular Cancer Therapeutics ·Andrew M. Kidger,Joanne M. Munck,Harpreet K. Saini,Kathryn Balmanno,Emma Minihane,Aurélie Courtin,Brent Graham,Marc O’Reilly,Richard Odle,Simon J. Cook	2019	17
3	Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction Cancer Drug Resistance ·Matthew J. Sale,Kathryn Balmanno,Simon J. Cook	2019	5
4	MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance Nature Communications ·Matthew J. Sale,Kathryn Balmanno,Jayeta Saxena,Eiko Ozono,Katarzyna Wojdyła,Rebecca E. McIntyre,Rebecca Gilley,Anna Woroniuk,Karen Howarth,Gareth Hughes,Jonathan R. Dry,Mark J. Arends,Pilar Caro,David Oxley,Susan Ashton,David J. Adams,Julio Sáez-Rodríguez,Paul D. Smith,Simon J. Cook	2019	41
5	Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome Cellular and Molecular Life Sciences ·Anne L. Ashford,Tom Dunkley,Mark Cockerill,Rachel Rowlinson,Lisa Baak,Raffaella Gallo,Kathryn Balmanno,Louise Goodwin,Richard A. Ward,Pamela A. Lochhead,Sylvie M. Guichard,Kevin Hudson,Simon J. Cook	2015	27
6	Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation Journal of Cell Science ·Claire L. Cope,Rebecca Gilley,Kathryn Balmanno,Matthew J. Sale,Karen Howarth,Mark Hampson,Paul D. Smith,Sylvie M. Guichard,Simon J. Cook	2013	66
7	Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance Oncogene ·Victoria Chell,Kathryn Balmanno,Annette S. Little,Michael Wilson,Simon Andrews,Laura Blockley,Mark Hampson,Paul R. Gavine,Simon J. Cook	2012	120
8	Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines International Journal of Cancer ·Kathryn Balmanno,Simon Chell,Annette S. Gillings,Shaista Hayat,Simon J. Cook	2009	115
9	The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1 Cellular Signalling ·Claire Chalmers,Rebecca Gilley,H. Nikki March,Kathryn Balmanno,Simon J. Cook	2006	52
10	ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest Oncogene ·Daniel E. Todd,Ruth M. Densham,Sarah A Molton,Kathryn Balmanno,Catherine Newson,Claire R. Weston,Andrew P. Garner,Linda A. Scott,Simon J. Cook	2004	74
11	Extracellular Signal-regulated Kinases 1/2 Are Serum-stimulated “BimEL Kinases” That Bind to the BH3-only Protein BimEL Causing Its Phosphorylation and Turnover Journal of Biological Chemistry ·Rebecca Ley,Katherine Ewings,Kathryn Hadfield,E. A. Howes,Kathryn Balmanno,Simon J. Cook	2004	173
12	Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells Oncogene ·Kathryn Balmanno,Simon J. Cook	1999	195
13	The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQTM in human leukaemia and colorectal carcinoma cell lines British Journal of Cancer ·EJ Estlin,Kathryn Balmanno,A H Calvert,Andrew G. Hall,John Lunec,DR Newell,A D Pearson,G. A. Taylor	1997	3
14	Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer Cancer Chemotherapy and Pharmacology ·Michael Millward,David R. Newell,Kally Yuen,Jane Matthews,Kathryn Balmanno,Christopher J. Charlton,Lindsey Gumbrell,Michael Lind,Fiona Chapman,M Proctor,D Simmonds,Brian M.J. Cantwell,A. Hilary Calvert	1995	18
15	Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481) European Journal of Cancer ·Michael Millward,David R. Newell,Vanaja Mummaneni,Linus N. Igwemezie,Kathryn Balmanno,Christopher J. Charlton,Lindsey Gumbrell,Michael Lind,F Chapman,M Proctor,D Simmonds,B.M.J. Cantwell,G. A. Taylor,C. McDaniel,Benjamin Winograd,Sanjeev Kaul,R.H. Barbaiya,A H Calvert	1995	12
16	Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results Cancer Treatment Reviews ·A H Calvert,Michael Lind,M. Millward,B.M.J. Cantwell,Lindsey Gumbrell,M Proctor,Dennis M. Simmons,F Chapman,Andrew Robinson,C. Chariton,Kathryn Balmanno,David R. Newell	1993	30
17	Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. Journal of Clinical Oncology ·David R. Newell,A D Pearson,Kathryn Balmanno,L Price,Ruth Wyllie,M.J. Keir,A. Hilary Calvert,Ian Lewis,CR Pinkerton,Michaël C.G. Stevens	1993	113
18	Phase II trial of trimelamol in refractory ovarian cancer British Journal of Cancer ·I R Judson,A H Calvert,M. Gore,Kathryn Balmanno,LA Gumbrell,Timothy Perren,E. Wiltshaw	1991	8
19	Estimation of the In Vitro and In Vivo Inhibitory Effects of Antifolates upon Thymidylate Synthase (TS) in Whole Cells Advances in experimental medicine and biology ·Geoffrey A. Taylor,A L Jackman,Kathryn Balmanno,L. R. HUGHES,A. Hilary Calvert	1989	12
20	BIOLOGICAL PROPERTIES OF 2-DESAMINO-2 SUBSTITUTED -5,8-DEAZAFOLATES THAT INHIBIT THYMIDYLATE SYNTHASE (TS) UCL Discovery (University College London) ·(unknown),G. L. Taylor,(unknown),J.A.M. Bishop,Graham M. F. Bisset,Krzysztof Pawełczak,Kathryn Balmanno,Hughes Lr,(unknown)	1988	3

About Kathryn Balmanno

Kathryn Balmanno is a scholar working on Oncology, Molecular Biology and Cell Biology, having authored 45 papers that have together received 3.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (18 papers), Cell death mechanisms and regulation (11 papers), Protein Kinase Regulation and GTPase Signaling (10 papers), Ubiquitin and proteasome pathways (7 papers), Cancer-related Molecular Pathways (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Neuroendocrine Tumor Research Advances (4 papers) and Lung Cancer Research Studies (4 papers). The work is most often cited by research in Oncology (956 citations), Molecular Biology (2.4k citations) and Cancer Research (375 citations). Kathryn Balmanno has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Simon J. Cook, Kathryn Hadfield, Claire R. Weston, Rebecca Gilley, Katherine Ewings, Annette S. Little, Matthew J. Sale, Paul D. Smith, Ceri M. Wiggins and E. A. Howes. Their work appears in journals such as Science, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact